[1] Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012 [J]. Int J Cancer, 2015, 136(5): E359-E386.
[2] Jemal A, Ma J, Siegel R, et al. Prostate cancer incidence rates 2 years after the US preventive services task force recommendations against screening [J]. JAMA Oncol, 2016, 2(12): 1657-1660.
[3] Golding B, Luu A, Jones R, et al. The function and therapeutic targeting of anaplastic lymphoma kinase (ALK) in non-small cell lung cancer (NSCLC) [J]. Mol Cancer, 2018, 17(1): 52-67.
[4] Lortet-Tieulent J, Soerjomataram I, Lin CC, et al. U.S. burden of cancer by race and ethnicity according to disability-adjusted life years [J]. Am J Prev Med, 2016, 51(5): 673-681.
[5] Okimoto RA, Bivona TG. Recent advances in personalized lung cancer medicine [J]. Per Med, 2014, 11(3): 309-321.
[6] Lin CC, Shih JY, Yu CJ, et al. Outcomes in patients with non-small-cell lung cancer and acquired Thr790Met mutation treated with osimertinib: a genomic study [J]. Lancet Respir Med, 2018, 6(2): 107-116.
[7] Pietrantonio F, di Nicolantonio F, Schrock AB, et al. ALK, ROS1, and NTRK rearrangements in metastatic colorectal cancer [J]. J Natl Cancer Inst, 2017, 109(12): 89-99.
[8] Zhang X, Cao J, Miller SP, et al. Comparative nucleotide-dependent interactome analysis reveals shared and differential properties of KRas4a and KRas4b [J]. ACS Cent Sci, 2018, 4(1): 71-80.
[9] Ali G, Proietti A, Pelliccioni S, et al. ALK rearrangement in a large series of consecutive non-small cell lung cancers: comparison between a new immunohistochemical approach and fluorescence in situ hybridization for the screening of patients eligible for crizotinib treatment [J]. Arch Pathol Lab Med, 2014, 138(11): 1449-1458.
[10]Hout DR, Schweitzer BL, Lawrence K, et al. Performance of a RT-PCR Assay in Comparison to FISH and Immunohistochemistry for the Detection of ALK in Non-Small Cell Lung Cancer [J]. Cancers(Basel), 2017, 9(8): 99-113.
[11]Solomon BJ, Mok T, Kim DW, et al. First-line crizotinib versus chemotherapy in ALK-positive lung cancer [J]. N Engl J Med, 2014, 371(23): 2167-2177.
[12]Paik JH, Choi CM, Kim H, et al. Clinicopathologic implication of ALK rearrangement in surgically resected lung cancer: a proposal of diagnostic algorithm for ALK-rearranged adenocarcinoma [J]. Lung Cancer, 2012, 76(3): 403-409.
[13]Mahe E. Comment on 'testing for ALK rearrangement in lung adenocarcinoma: a multicenter comparison of immunohistochemistry and fluorescent in situ hybridization' [J]. Mod Pathol, 2014, 27(10): 1423-1424.
[14]Sullivan HC, Fisher KE, Hoffa AL, et al. The role of immunohistochemical analysis in the evaluation of EML4-ALK gene rearrangement in lung cancer [J]. Appl Immunohistochem Mol Morphol, 2015, 23(4): 239-244.
[15]Rothschild SI. Targeted therapies in non-small cell lung cancer-beyond EGFR and ALK [J]. Cancers (Basel), 2015, 7(2): 930-949.
[16]Sasaki T, Koivunen J, Ogino A, et al. A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors [J]. Cancer Res, 2011, 71(18): 6051-6060.
[17]Gainor JF, Varghese AM, Ou SH, et al. ALK rearrangements are mutually exclusive with mutations in EGFR or KRAS: an analysis of 1,683 patients with non-small cell lung cancer [J]. Clin Cancer Res, 2013, 19(15): 4273-4281.
[18]Yoshida A, Tsuta K, Nakamura H, et al. Comprehensive histologic analysis of ALK-rearranged lung carcinomas [J]. Am J Surg Pathol, 2011, 35(8): 1226-1234. |
